KM Research Hub
← 返回论文库
已完成 入排:待复核 图源:可得 入排置信度 0.70

Automated Imaging as an Adjunct to Serum and Clinical Biomarkers: A New Validated Prediction Tool for Metastatic Castration-Resistant Prostate Cancer.

Michael J Morris, Jessica Flynn, Binsheng Zhao, Aseem Anand, Karl Sjöstrand, Steven M Larson, Ashley M Regazzi, Gary V Borzillo, Autumn Park, Lawrence H Schwartz, Glenn Heller

Clin Cancer Res 32(3) 562-569

PMID41324553
PMCIDPMC12758974
DOI10.1158/1078-0432.CCR-25-2890
发表日期2025-12-01
入排依据:The record describes a study that develops a predictive model using data from two Phase III randomized trials (COU-AA-302 and A031201), but it is not the original formal result report of either trial. The title and abstract focus on model development and validation, not on reporting the primary efficacy results of a drug-containing intervention. The drug intervention is not explicitly named or evaluated in the abstract.
摘要

摘要

PURPOSE: Contemporary prostate cancer prognostic models do not include imaging and generally are based on pretreatment parameters. We sought to develop an externally validated model that used novel quantification of soft-tissue and bone disease, integrated with standard clinical and serum biomarkers, at baseline and up to 6 months of treatment. EXPERIMENTAL DESIGN: Two randomized phase 3 trials, Cougar COU-AA-302 (NCT00887198; for derivation) and Alliance A031201 (NCT01949337; for validation), were used to evaluate the added value of early on-treatment bone imaging and more than 1,000 radiomics features on CT, used in conjunction with clinical and serum biomarkers in first-line metastatic castration-resistant prostate cancer. Predictive accuracy measures were computed to determine whether these early on-treatment biomarkers could reliably sort patients into risk groups that inform overall survival (OS) and whether the patient-specific biomarker risk score could precisely predict their OS time. RESULTS: Imaging improved patient risk stratification but did not improve individual survival predictions. The strongest risk prediction model was developed for patients with bone-only metastases. This model was also the least complex, relying on just 16 risk factors, whereas all other models were high-dimensional, incorporating approximately 1,100 intercept and 1,100 slope features from the early on-treatment biomarker trajectories. CONCLUSIONS: Pretreatment and early on-treatment serum and automated quantitative imaging markers can well discriminate risk of death. Imaging improves this risk categorization relative to serum biomarkers alone. Such models can give early outcome predictions and can be used in future trials that involve imaging, even using traditional techniques such as bone scintigraphy.

KM 提取结果

3 个 Figure · 6 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 2

Figure 2. Kaplan-Meier curves for the 582 A031201 patients stratified by risk. Figure 2A: risk groups derived including imaging. Figure 2B: risk groups derived excluding imaging. Abbreviations: Md, median; mos, months.

A

overall survival

Figure 2 · Panel A

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 3:off origin start
查看结果
B

overall survival

Figure 2 · Panel B

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 3:off origin start
查看结果
KM Figure2 个面板

Figure 4

Figure 4. Kaplan-Meier curves for the 182 A031201 patients with bone-only metastases, stratified by risk. Figure 4A: risk groups derived including imaging. Figure 4B: risk groups derived excluding imaging. Abbreviations: Md, median; mos, months

A

survival

Figure 4 · Panel A

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel A 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 3:off origin start
查看结果
B

survival

Figure 4 · Panel B

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel B 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 3:off origin start
查看结果
KM Figure2 个面板

Figure 5

Figure 5. Kaplan-Meier curves for the 352 A031201 patients with soft tissue metastases (± bone metastases), stratified by risk. Figure 5A: risk groups derived including imaging. Figure 5B: risk groups derived excluding imaging. Abbreviations: Md, median; mos, months.

A

Overall Survival

Figure 5 · Panel A

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel A 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 3:off origin start
查看结果
B

Overall Survival

Figure 5 · Panel B

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel B 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 3:off origin start
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Flowchart showing patient populations eligible for this analysis. Abbreviations: CT, computed tomography; mo, months.
非 KM Figure
Figure 3Figure 3. Observed OS and the estimated restricted mean survival curve from the model risk scores for the 582 A031201 patients. X indicates observed death time and circle indicates censored last follow-up time, both mapped to the vertical axis. Figure 3A: used prediction model including imaging. Figure 3B: used prediction model excluding imaging.
非 KM Figure